|Bid||0.00 x 1400|
|Ask||0.00 x 3100|
|Day's Range||36.72 - 37.21|
|52 Week Range||31.43 - 48.25|
|Beta (5Y Monthly)||0.31|
|PE Ratio (TTM)||37.39|
|Earnings Date||Feb 01, 2017 - Feb 06, 2017|
|Forward Dividend & Yield||2.03 (5.52%)|
|Ex-Dividend Date||Nov 12, 2020|
|1y Target Est||48.17|
With three vaccine candidates out with a first look at efficacy data, Wall Street is more optimistic about the light at the end of the pandemic tunnel.
The Zacks Analyst Blog Highlights: UnitedHealth, CRM, GSK, Square and American Electric Power
Glaxo (GSK) is developing vaccine against respiratory syncytial virus for pediatric patients, pregnant women and older adults. The candidates hold significant potential.